ストックスクリーナーアプリを入手
18.37
5.43%
-1.055
前日終値:
$19.43
開ける：
$19.37
24時間の取引高:
311.36K
Relative Volume:
1.38
時価総額：
$737.25M
収益：
-
当期純損益:
$-102.09M
株価収益率:
-17.50
EPS:
-1.05
ネットキャッシュフロー:
$-108.72M
1週間 パフォーマンス:
+32.16%
1か月 パフォーマンス:
+33.41%
6か月 パフォーマンス:
+89.58%
1年 パフォーマンス:
+378.39%
1日の値動き範囲:
$17.86
$19.41
1週間の範囲:
$14.09
$21.50
52週間の値動き範囲:
$2.74
$21.50
Dbv Technologies Adr Stock (DBVT) Company Profile
名前
Dbv Technologies Adr
セクター
電話
33(0)155427878
住所
107 AVENUE DE LA REPUBLIQUE, CHATILLON
DBVT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DBVT
Dbv Technologies Adr
|
18.37 | 779.59M | 0 | -102.09M | -108.72M | -1.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Dbv Technologies Adr Stock (DBVT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-03 | 開始されました | Guggenheim | Buy |
| 2025-05-29 | 再開されました | Goldman | Sell |
| 2023-01-04 | アップグレード | Societe Generale | Hold → Buy |
| 2022-12-16 | ダウングレード | Goldman | Neutral → Sell |
| 2022-05-10 | ダウングレード | Goldman | Buy → Neutral |
| 2021-09-14 | アップグレード | Societe Generale | Hold → Buy |
| 2021-01-22 | ダウングレード | Societe Generale | Hold → Sell |
| 2020-11-02 | アップグレード | Societe Generale | Sell → Hold |
| 2020-08-06 | ダウングレード | Societe Generale | Buy → Sell |
| 2020-08-05 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-03-17 | ダウングレード | Stifel | Buy → Hold |
| 2020-01-09 | アップグレード | Stifel | Hold → Buy |
| 2019-12-16 | 開始されました | Citigroup | Buy |
| 2019-09-05 | 再開されました | Morgan Stanley | Equal-Weight |
| 2019-06-17 | 開始されました | Goldman | Buy |
| 2018-12-20 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2018-12-20 | ダウングレード | BofA/Merrill | Buy → Underperform |
| 2018-12-20 | ダウングレード | Jefferies | Buy → Hold |
| 2018-12-20 | ダウングレード | Stifel | Buy → Hold |
| 2017-10-31 | アップグレード | Societe Generale | Sell → Hold |
| 2017-10-24 | ダウングレード | Societe Generale | Buy → Sell |
| 2017-10-23 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2017-06-23 | 開始されました | Deutsche Bank | Buy |
| 2017-03-16 | アップグレード | Societe Generale | Hold → Buy |
| 2016-09-26 | 開始されました | JMP Securities | Mkt Outperform |
| 2015-12-03 | 開始されました | Barclays | Overweight |
| 2015-10-23 | 開始されました | BofA/Merrill | Buy |
すべてを表示
Dbv Technologies Adr (DBVT) 最新ニュース
European Companies Trading In The US Notched Gains This Week - Finimize
What is DBV Technologies ADR (DBVT) Stock Return on Shareholders’ Capital? - setenews.com
Are Smart Investors Making the Right Decision? Snow Lake Resources Ltd (LITM) - setenews.com
Total assets of DBV Technologies SA Sponsored ADR – LSX:A40WEX - TradingView
DBV Technologies (NASDAQ:DBVT) Coverage Initiated at Guggenheim - Defense World
Check Out Netskope Inc (NTSK)’s Trade Data Rather Than the Analysts’ Views - Setenews
Taking on analysts’ expectations and winning: DBV Technologies ADR (DBVT) - setenews.com
DBV Technologies stock initiated with Buy rating at Guggenheim - Investing.com
12 Health Care Stocks Moving In Friday's Pre-Market Session - Sahm
Healthy Upside Potential: Safe Pro Group Inc (SPAI) - Setenews
DBV Technologies S.A. (NASDAQ:DBVT) Given Consensus Recommendation of “Hold” by Brokerages - Defense World
RFK Jr Rejects Early Exposure Theory On Rising Peanut Allergies, Says Aluminum-Based Vaccines Are The Reason - Sahm
European ADRs Slip As Gains And Losses Balance Out - Finimize
US Investors Show Renewed Interest In European ADRs - Finimize
Pre Market Movers: SLRX, SI, ELDN Swing Big - RTTNews
Why LightPath Technologies Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket - inkl
DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years - The Manila Times
DBV Technologies (NASDAQ: DBVT) marks last patient visit in 654-patient VITESSE study - Stock Titan
DBV Technologies Announces Last Patient Visit Completed in - GlobeNewswire
DBV Technologies annonce la dernière visite du dernier patient dans l'essai clinique de phase 3 VITESSE du patch VIASKIN® Peanut chez les enfants âgés de 4 à 7 ans allergiques aux arachides - GlobeNewswire Inc.
DBV Technologies completes last patient visit in VITESSE trial - Investing.com
Analysts Offer Insights on Healthcare Companies: Veeva Systems (VEEV), ALX Oncology Holdings (ALXO) and Cencora (COR) - The Globe and Mail
DBV technologies S.A. (ADR) (DBV1.SG) Balance Sheet - Yahoo! Finance Canada
Biotech Shines As UK And European ADRs See Mixed Results - Finimize
DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference - The Manila Times
DBV (NASDAQ: DBVT) to join Guggenheim Healthcare Innovation Conf.; webcast, 90-day replay - Stock Titan
DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer - 24matins.uk
DBV Technologies (NASDAQ: DBVT) appoints Kevin Trapp to lead Viaskin Peanut commercialization - Stock Titan
European ADRs Show Mixed Moves In Active Sectors - Finimize
DBV Technologies Appoints Dr. Philina Lee to Board - The Globe and Mail
DBV Technologies Reports Q3 2025 Financial Results - MSN
DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors - The Manila Times
DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting - The Manila Times
DBV (NASDAQ: DBVT) to present Phase 2 VIASKIN Peanut infant study plan at ACAAI 2025 - Stock Titan
DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq - markets.businessinsider.com
Health Care And Telecom Drive European ADR Gains In The US - Finimize
European ADRs Mostly Flat As Gains And Losses Trade Off - Finimize
DBV Technologies Announces Sale of approximately $30 - GlobeNewswire
DBV Technologies (NASDAQ: DBVT) sells ~$30M in ADSs; dilution ~5.96% - Stock Titan
Dbv Technologies Adr (DBVT) 財務データ
収益
当期純利益
現金流量
EPS
Dbv Technologies Adr (DBVT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Mohideen Pharis | Chief Medical Officer |
Nov 21 '25 |
Sale |
2.77 |
1,624 |
4,498 |
101,529 |
| Mohideen Pharis | Chief Medical Officer |
Jul 29 '25 |
Sale |
2.22 |
464 |
1,030 |
109,649 |
| Mohideen Pharis | Chief Medical Officer |
May 22 '25 |
Sale |
1.84 |
397 |
730 |
110,113 |
| Mohideen Pharis | Chief Medical Officer |
Jan 30 '25 |
Sale |
0.85 |
600 |
510 |
110,510 |
1.08%
0.91%
大文字化:
|
ボリューム (24 時間):